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Abstract 
Review on RACGAP1, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Keywords: RACGAP1; meningioma; colorectal 
cancer; melanoma; Hepatocellular carcinoma; 
gastric cancer 
Identity 
Other names: CYK4, HsCYK-4, ID-GAP, 
MgcRacGAP, KIAA1478, ID-GAP, RCGAP1 
(Toure A et al., 1998; Toure A et al., 2001; Burkard 
ME et al., 2009) 
HGNC (Hugo): RACGAP1 
Location: 12q13.12 
Local order 
According to NCBI Map Viewer,  genes locating in 
the region next to RACGAP1 in centromere to 
telomere direction on 12q13 are: TMBIM6 
(12q13.12), transmembrane BAX inhibitor motif 
containing 6; FAIM2 (12q13), Fas apoptotic 
inhibitory molecule 2; AQP2 (12q13.12), aquaporin 
2 (collecting duct); AQP5 (12q13), aquaporin-5; 
RACGAP1; ASIC1 (12q12), acid sensing ion 
channel subunit ; SMARCD1 (12q13-q14), 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily d, membre 1; 
GPD1 (12q13.12), glycérol-3-phosphate 
dehydrogenase 1; CERS5 (12q13.12), ceramide 
synthase 5. 
DNA/RNA 
Description 
According to NCBI Map Viewer, RACGAP1 maps 
to NC_000012.12 in the region between 49961496 
and 50100711 on the minus strand and spans 56,214 
bases. The total number of exons is 22. As reported 
by SABiosciences' database, the transcription factor 
binding sites, in the RACGAP1 gene promoter, are: 
STAT3, FOXO1, GATA1, TBP, FOXD3, FOXO4, 
SRY, REPIN1 (AP-4). 
Transcription 
RACGAP1 gene has 12 alternative transcript 
variants, which encode 4 isoforms of Rac GTPase 
activating protein 1. The locus of the reference 
variant (variant 1) is in NM_013277 and it has 
3361bp. Variant 2 lacks an exon and contains an 
alternate exon in the 5' UTR, while variant 3 lacks 
two exons and uses an alternate splice site in the 5' 
UTR, variant 4 lacks two exons in the 5' UTR, 
variant 5 lacks two exons and contains an alternate 
exon in the 5' UTR and variant 6 lacks two exons and 
uses two alternate splice sites in the 5' UTR. 
Variants 7, 8 and 9 lack two exons and use an 
alternate splice site in the 5' UTR. All the transcript 
variants from 1 to 9 encode for isoform a. The 10th 
variant lacks three exons in the 5' region and initiates 
translation at a downstream start codon compared to 
variant 1. Its encoded isoform b has a shorter N-
terminus than isoform a.  
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 A schematic illustration of RACGAP1 gene The RACGAP1 gene is shown with red bar and it is flanked by AQP6 and AQP5 
genes on the left side and ASIC1 and SMARCD1 genes on the right side. RACGAP1's location is on 12q13.12, and it has 22 
exons (NCBI). 
 
The 11th variant lacks two exons, contains an 
alternate exon and uses an alternate splice site in the 
5' region. It initiates translation at an alternate start 
codon. Its encoded isoform c has a longer N-
terminus than isoform a. 
Lastly, variant 12 lacks three exons in the 5' region 
and initiates translation at an alternate downstream 
start codon. The encoded isoform d has a distinct N-
terminus and is shorter than isoform a. Transcription 
is regulated by STAT3, FOXO1, GATA-1, TBP, 
FOXD3, FOXO4, SRY and AP-4 binding sites 
(NCBI database). 
Pseudogene 
FKSG42 is a RACGAP1 pseudogene as reported by 
HGNC. It is located in 12q12 chromosome and it has 
1 exon. 
Protein 
RACGAP1 protein plays an important role in the 
Rho GTPase activation cycle. In fact, it binds 
activated forms of Rho GTPases and stimulates GTP 
hydrolysis. Thus, it inhibits Rho-mediated signals. 
Regarding RACGAP1 protein function, it has a 
regulatory role in the starting of cytokinesis, 
regulates spermatogenesis and proliferation of 
neuronal cells, as well as it controls cell growth and 
differentiation of hematopoietic cells (Boguski M.S. 
et al., 1993; Hamanaka R. et al., 1994). Lately, it was 
found that high levels of RACGAP1 is correlated 
with a worse prognosis in patients with high grade 
meningiomas (Brennan IM et al., 2007), while Wang 
SM et al. showed that RACGAP1 upregulation is 
associated with relapse of hepatocellular cancer 
(Wang SM et al., 2011). 
Description 
According to Swiss Prot database the protein 
contains 632 amino acids and its molecular mass is 
71027 Da. About protein's structure, it is a 
heterotetramer of two of RACGAP1 and KIF23 ID: 
41068> (Kinesin Family membre 23) molecules. It 
is found in the centralspindlin complex, a motor 
complex required for the assembly of the mitotic 
spindle (Nature Reviews Molecular Cell Biology, 
2009). It is associated with alpha-, beta- and gamma-
tubulin and microtubules. The protein interacts via 
its Rho-GAP domain with RND2 (Rho family 
GTPase 2) and PRC1 (Protein Regulator of 
Cytokinesis). Its GAP activity towards CDC42 (Cell 
Division Cycle42 effector protein) is inhibited by 
interaction with PRC1 in vitro, which may be 
important for maintaining a normal spindle 
morphology.  
Furthermore, RACGAP1 associates with AURKB 
(Aurora Kinase B) during M phase and interacts with 
SLC26A8 (Solute Carrier family 26 member 8) via 
its N-terminus and RAB11FIP3 (RAB11 Family 
Interacting Protein 3).  
During anaphase and cytokinesis, the protein binds 
to ECT2 (Epithelial Cell Transforming 2) in a 
microtubule-dependent manner and it is enhanced by 
phosphorylation by PLK1 (Polo-like Kinase 1). 
Lastly, it interacts directly with KIF23. 
 
The Crystal Structure Of The Human Rac GTPase 
Activating Protein 1 (RACGAP1) (PROTEIN DATA BANK) 
Expression 
It is highly expressed in the testis, thymus, placenta, 
gastrointestinal tract, urinary tract, uterus, cervix, 
skin, tonsil, nasopharynx, bone marrow and lymph 
nodes.  
It is found at lower levels in spleen and peripheral 
blood lymphocytes. In testis, RACGAP1 expression 
is restricted to germ cells with the highest levels of 
expression found in spermatocytes.  
Its expression is monitored during the cell cycle and 
it peaks at G2/M phase (Toure A et al., 1998; Toure 
A et al., 2001; Naud N et al., 2003; Zhang P et al., 
2015). 
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Localisation 
RACGAP1 colocalizes with RND2 in Golgi-derived 
proacrosomal vesicles and the acrosome. During 
interphase, it is localized to the nucleus and 
cytoplasm along with microtubules, while in 
anaphase it is organized to the central spindle and in 
telophase and cytokinesis to the midbody. 
Colocalization of RACGAP1 with RhoA occurs at 
the myosin contractile ring during cytokinesis and 
with ECT2 at the mitotic spindles during 
anaphase/metaphase, at the cleavage furrow during 
telophase, and to the midbody at the end of 
cytokinesis. Lastly, it neighbours with CDC42 to 
spindle microtubules from prometaphase to 
telophase (Mishima M et al., 2002). 
Function 
MgcRacGAP is a component of the central spindlin 
complex that serves as a microtubule-dependent and 
Rho-mediated signaling, required for the myosin 
contractile ring formation during the cytokinesis. To 
specify, it helps for a proper attachment of the 
midbody to the cell membrane during cytokinesis. 
GAP1 plays also key role in controlling cell growth 
and differentiation of hematopoietic cells, 
adipocytes and myoblasts. It may regulate the cell 
proliferation in the nervous system as well as the 
sulfate transport in male germ cells. In addition, 
MgcRacGAP, by inhibiting the activity of RAC1 and 
CDC42, which act on the microtubule and actin 
cytoskeleton, controls cell proliferation, adhesion 
and motility. It may play a role in regulating cortical 
activity throughRHOA-mediated signals during 
cytokinesis. At last, it is found to be essential for the 
early stages of embryogenesis (Toure A et al., 1998; 
Kawashima T et al., 2000; Hirose K et al., 2001; 
Yuce O et al., 2005). 
Homology 
According to NCBI, the RACGAP1 gene is 
conserved in chimpanzee, Rhesus monkey, dog, 
cow, mouse, rat, chicken, zebrafish, fruit fly, 
mosquito, and frog. 
Mutations 
Note 
The mammalian Polo-like kinase PLK1 (Hamanaka 
R et al., 1994) was shown recently to be an essential 
activator of RhoA (Brennan IM et al., 2007; Burkard 
ME et al., 2007; Petronczki et al., 2007; Santamaria 
et al., 2007). Inhibition of PLK1 prevents ECT2 
association with HsCyk-4 (alias of RACGAP1) and 
blocks its recruitment to the central spindle (Brennan 
IM et al., 2007; Burkard ME et al., 2007; Petronczki 
et al., 2007; Santamaria et al., 2007), proposing that 
PLK1 might serve as a stimulatory kinase. Benjamin 
A. Wolfe et al., examined the mechanism by which 
PLK1 stimulates association between ECT2 and 
HsCyk-4 during anaphase to trigger the cytokinesis 
(Benjamin A. Wolfe et al., 2009). In the meanwhile, 
Lowery DM and colleagues found that the N 
terminus (Nt) of HsCyk-4 contains seven consensus 
motifs for PLK1 phosphorylation (Lowery DM et 
al., 2005). Benjamin et al., trying to determine which 
sites are phosphorylated by PLK1, confirmed that 
only peptides containing amino acids 139-174 of 
HsCyk-4 did so. Within this region, they took up four 
hypothetical PLK1 phosphorylation sites (Ser149, 
Ser157, Ser164, and Ser170), which are well 
conserved across species, and they altered them. 
Mutation of any of these four residues was 
insufficient on its own to prevent PLK1-stimulated 
binding. The results show that, in vitro 
phosphorylation of HsCyk-4-4A (amino acids 111-
188) by PLK1 was dramatically reduced. 
Conversely, they mutated these four serine residues 
to Asp (HsCyk-4-4D) so as to mimic the 
phosphorylated state, and generated a form of 
HsCyk-4 able to associate with ECT2-BRCT even in 
the absence of PLK1 phosphorylation.Based on 
these results they conclude that PLK1 
phosphorylates multiple serine residues in the N 
terminus of HsCyk-4 in vitro, thereby stimulating its 
association with ECT2. 
Implicated in 
Meningioma 
Disease 
Meningiomas are a diverse set of tumors arising 
from meninges, the membranous layers covering the 
brain and the spinal cord (Cushing H, 1922). 
Meningiomas specifically derive from the arachnoid 
granulations of the arachnoid matter (Buetow MP et 
al., 1991). These tumors are usually benign in nature 
and slowly growing; however, a small percentage are 
malignant (Goldsmith BJ et al., 1994). The 
classification of mengiomas is based upon the WHO 
classification system: Grade I (Benign) 90% - 
meningothelial, fibrous, transitional, 
psammomatous, angioblastic, Grade II (Atypical) 
7% - chordoid, clear cell, atypical (includes brain 
invasion), Grade III (Anaplastic/malignant) 2% - 
papillary, rhabdoid, anaplastic (most aggressive). 
Most meningiomas produce no symptoms 
throughout a person's life, and if accidentantly 
found, require no treatment other than periodic 
observation. Typically, symptomatic meningiomas 
are treated with either radiosurgery or conventional 
surgery. 
Prognosis 
Ke HL et al. did a research on how RACGAP1 
expression is correlated in the meningiomas (Ke HL 
et al.., 2013). The results showed a higher 
RACGAP1 expression in Grade III mengingioma 
comparing to Grade I. Higher levels of RACGAP1 
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mRNA were significantly correlated with tumor 
size, higher Simpson grade, histological type and 
clinical course (P < 0.05). Additionally, patients with 
high levels of RACGAP1 mRNA had a significantly 
worse survival than the lower level ones (P = 0.008). 
Upon these results, the researchers suggested that 
RACGAP1 may be used as a potential predictive 
biomarker for disease aggressiveness and patients' 
prognosis. 
Hepatocellular carcinoma 
Disease 
Hepatocellular carcinoma (HCC), also called 
malignant hepatoma, is the most common type of 
liver cancer. Most cases of HCC are secondary to 
either a viral hepatitis infection (hepatitis B or C) or 
cirrhosis. The clinical manifestations of HCC are 
usually jaundice, ascites, blood clotting 
abnormalities, loss of appetite, unintentional weight 
loss, abdominal pain, especially in the right upper 
quadrant, nausea, vomiting, or tiredness. Prognosis 
and treatment options for HCC depend on staging 
but also on other factors such tumor grade, Child-
Pugh score and overall patient's performance status 
and comorbidities. High-grade tumors will have a 
poor prognosis, while low-grade tumors may go 
unnoticed for many years (Naud N et al., 2003) 
Prognosis 
It has been proved that relapse of Hepatocellular 
Carcinoma (HCC) increases with higher HBV viral 
load (Yu SJ et al., 2014). Wang SM et al., proved 
that high RACGAP1 expression associates with high 
risk of relapse of HBV-positive HCC patients (Wang 
SM et al., 2011). According to their research, 
silencing of RACGAP1 in Hep3B and MHCC97-H, 
in cancer cells with high endogenous RACGAP1 
expression, inhibited cell migration and invasion. 
This outcome suggests that RACGAP1  besides 
being an independent informative prognostic 
biomarker, it could also be a potential molecular 
target for designing therapeutic strategies for HCC. 
Colorectal cancer 
Disease 
Colorectal cancer is the development of cancer in the 
large bowel. Signs and symptoms may include 
melena (black stools), a change in bowel habits, 
pain, weight loss, cachexia, or persistent fatigue. 
Treatments available for colorectal cancer include 
surgery, radiation therapy, chemotherapy, targeted 
therapy or combination of above depending on the 
disease site and stage. Cancers confined to the wall 
of the colon are usually curable with surgery while 
cancer that has spread distantly are usually incurable. 
In very advanced stages management might simply 
focus on quality of life and symptoms control 
(National Cancer Institute, 2014). 
Prognosis 
RACGAP1 plays a key role in regulating various 
cellular functions including cytokinesis, 
transformation, invasive migration and metastasis. 
In the study of Imaoka H et al., the function and 
clinical significance of RACGAP1 expression in 
colorectal cancer (CRC) was investigated (Imaoka H 
et al., 2015).  
Reduced RACGAP1 expression by siRNA in CRC 
cell lines showed significantly decreased cellular 
proliferation, migration and invasion whereas 
increased expression of RACGAP1 was highly 
associated with worse prognosis.  
In multivariate analyses, the researchers found that 
high levels of RACGAP1 was an independent 
prognostic biomarker for lymph node metastasis and 
worse disease-free and relapse free survival in CRC. 
Gastric cancer 
Disease 
Stomach cancer, also known as gastric cancer, 
develops from the lining of the stomach. Early 
symptoms may include heartburn, upper abdominal 
pain, nausea and loss of appetite. Later signs and 
symptoms may include weight loss, vomiting, 
difficulty swallowing, and melena.  
The cancer may spread from the stomach to other 
parts of the body, particularly the lymph nodes, liver, 
lungs, peritoneum or bones etc. Worldwide, stomach 
cancer is the fifth leading cause of cancer and the 
third leading cause of death from cancer. Regarding 
its management, this disease is not usually curable 
unless it is found at a very early stage.  
Unfortunately, the majority of patients are diagnosed 
when the disease has already become advanced. 
Treatment options include surgery, chemotherapy,  
radiation therapy (National Cancer Institute, 2014) 
and lately biological therapy and immunotherapy. 
Prognosis 
Saigusa S et al. studied the clinical significance of 
RACGAP1 expression at the invasive form of gastric 
cancer (Saigusa S et al., 2015). Patients with positive 
RACGAP1 expression at the invasive form, had 
significantly poorer prognosis than those without 
expression (P < 0.0001). In the multivariate analysis, 
lymph node metastasis (P = 0.0106), distant 
metastasis (P = 0.0012) and positive RACGAP1 
expression (P = 0.001) were independent prognostic 
factors. Based on these results, researchers conclude 
that RACGAP1 expression may play a crucial rule in 
the progression of gastric cancer. 
Melanoma 
Disease 
Melanoma is a type of cancer that develops from the 
melanine-containing skin cells, known as 
melanocytes. Early signs of melanoma are changes 
to the shape or color of an existing mole or, in the 
case of nodular melanoma, the appearance of a new 
RACGAP1 (Rac GTPase activating protein 1) Strimpakos A, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(10) 510 
 
lump anywhere on the skin. At later stages, the mole 
may itch, ulcerate or bleed (National Cancer 
Institute, 2015). Melanomas are usually caused by 
DNA damage resulting from long-standing exposure 
to ultraviolet (UV) light from the sun. Confirmation 
of the clinical diagnosis is based on a skin biopsy.  
Treatment of melanoma may include surgery, 
chemotherapy, immunotherapy and radiotherapy, 
depending again on disease  and patients' stage and 
status. 
Prognosis 
Melanoma cell migration across vascular endothelial 
cells is crucial for tumor metastasis. According to 
Zhang P et al., RACGAP1-driven focal adhesion 
formation, promotes melanoma cells to migrate 
through vascular endothelium by causing adherens 
junction disassembly (Zhang P et al., 2015). After, 
depletion of RACGAP1 with RACGAP1-targeting 
siRNA or overexpression of RACGAP1 mutant 
(T249A), melanoma cell transendothelial migration 
and disorganization of adherens junctions was 
reduced. In addition, RACGAP1 promoted the 
activation of RhoA, FAK, PXN (paxillin) and 
triggered focal adhesion formation and cytoskeletal 
rearrangement. By overexpressing FRNK (FAK-
related non-kinase) in endothelium, they proved that 
RACGAP1 damages the endothelial barrier and 
facilitates melanoma transmigration in a focal 
adhesion-dependent manner. 
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